Arterial hypertension in children

Maristella Santi, Barbara Goeggel Simonetti, Corinna F.P. Leoni-Foglia, Mario G. Bianchetti, and Giacomo D. Simonetti

Purpose of review
Although arterial hypertension is less common in children than in adults, there is growing concern about elevated blood pressure (BP) in children and adolescents not only because of the association of elevated values with the overweight epidemic, but also as cardiovascular functions are determined in childhood and track into adulthood. The purpose of the review is to discuss new aspects of childhood hypertension.

Recent findings
Guidelines advocate determining BP in children as part of routine health maintenance. This recommendation was recently subject to review by the US Preventive Services Task Force. It was concluded that evidence is insufficient to assess the benefits of this screening. In our opinion, however, assessing BP is part of any thorough physical examination.

Sophisticated approaches demonstrate the role of sympathetic nervous system overdrive in the field of sympathetic cardiovascular modulation of childhood arterial hypertension.

Summary
Elevated BP in children is increasing in frequency and is now recognized as having relevant short-term and long-term consequences. Although efforts to address the childhood overweight epidemic may eventually reduce the number of young patients with hypertension, improved therapies for childhood hypertension also offer the potential for preventing or ameliorating early cardiovascular disease.

Keywords
adolescent, cardiovascular disease, children, epidemiology, hypertension, overweight, sympathetic nervous system

INTRODUCTION
Arterial hypertension affects about 20% of adults and is a leading cause of morbidity and mortality [1]. Although hypertension is less common in children than in adults, there is growing concern about elevated blood pressure (BP) and hypertension in children and adolescents because of the association of elevated BP with the overweight epidemic [2,3]. Moreover, it has been hypothesized that cardiovascular functions are determined in childhood and track into adulthood. Children with high BP values have a greater risk to have high (or too high) BP levels in adulthood, as indicated by the fact that almost half of adults with arterial hypertension had high BP values in childhood [3–5]. Tracking of BP begins in early childhood, at about the age of 5 years [6]. Consequently, prevention of adult cardiovascular diseases should begin early in childhood by counseling healthy lifestyle and avoiding preventable cardiovascular risk factors [3,7].

Screening for high BP at regular intervals in childhood is currently a matter of debate and will be further discussed in this review together with the definition of arterial hypertension, its association with sympathetic nervous system overactivation and its consequences.

Measurement of blood pressure and screening for hypertension in childhood
In childhood, the recommended method for BP assessment is auscultatory with Korotkoff 1 applied for SBP and Korotkoff 5 applied for DBP.

If an oscillometric device is used, the monitor needs to be validated; additionally, if hypertension...
is detected by the oscillometric method, it needs to be confirmed using the auscultatory method. Finally, the appropriate cuff size according to arm width (40% of the arm circumference) and length (4 x 8 cm, 6 x 12 cm, 9 x 18 cm, 10 x 24 cm, to cover 80–100% of the individual’s arm circumference) should be used [8]. Arterial hypertension in childhood is defined by at least three measurements at different times above the 95th centile adapted for age, height and sex. White coat hypertension and, more rarely, masked hypertension should be ruled out by 24-h ambulatory BP measurement (ABPM), particularly in older children. ABPM can be easily performed from the age of about 5 years onward and normal values for children are available [8].

In many industrialized countries, current guidelines advocate determining BP in children after the age of 3 years during each healthcare visit to screen for arterial hypertension [8,9]. This rather logical and intuitive suggestion was recently subject to intense scientific review by the US Preventive Services Task Force. The conclusion provided in the report is that ‘current evidence is insufficient to assess the balance of benefits and harms of screening for elevated BP in apparently healthy children and adolescents to prevent subsequent cardiovascular disease in childhood or adulthood’ [10]. This conclusion, which is largely based on the lack of data from longitudinal, randomized trials to support this practice, has been widely disputed [11,12–14,15].

In our opinion, this review fails to acknowledge that measurement of BP, a cheap and integral part of any careful physical examination, is too infrequently recorded in everyday pediatric practice. In addition, in many countries routine metabolic blood screenings (more invasive and expensive) for inherited disorders that are rarer than arterial hypertension are performed in newborn infants. Furthermore, the limitations of the analysis performed by the US Preventive Services Task Force deserve some comment. In the following, we aim at discussing these three issues.

Physicians are trained to monitor the development and the growth of children and youth using, among others, weight, height, head circumference, body temperature, respiratory rate, pulse rate and BP. Pediatric reference tables for these parameters, including BP, are available worldwide. Meanwhile, pediatricians can avoid unfriendly BP tables and interpret user-friendly BP measurements by using a mnemonic formula, online calculators or applications for smartphones [16,17].

BP measurement in children is part of routine health maintenance and is associated with no harm. In children with conditions increasing the risk of high BP – including premature birth, low birth weight, congenital heart disease, kidney diseases and treatment with drugs known to raise BP – checks begin during infancy (Table 1). Further factors predisposing to arterial hypertension in school-age children and adolescents are excessive body weight and a family history of elevated BP. In everyday clinical practice, BP is infrequently recorded in children and adolescents and, in our opinion, the conclusions raised by the US Preventive Services Task Force indirectly suggest that determination of BP is often unnecessary in children and adolescents. Our experience at a tertiary referral center with a catchment area of, approximately, one million people is in contrast to this conclusion. At this center, two or more asymptomatic cases of severe secondary hypertension with relevant target organ damage are encountered every year, supporting the notion that secondary arterial hypertension may go unrecognized in childhood [18].

Nowadays, most countries provide an expanded but rather expensive universal newborn metabolic screening for conditions such as adrenal hyperplasia, cystic fibrosis, galactosemia, hypothyroidism and phenylketonuria [19]. The frequency of arterial hypertension in children and adolescents is considered to be one in 50–100 individuals [8,9]. Thus, it appears surprising that rather expensive screening recommendations are used to identify rare or very
Table 1. Conditions under which children 3 years of age or less should have blood pressure measured

<table>
<thead>
<tr>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recurrent urinary tract infections</td>
</tr>
<tr>
<td>Hematuria or proteinuria</td>
</tr>
<tr>
<td>Known renal disease or urologic malformations</td>
</tr>
<tr>
<td>Family history of congenital renal disease</td>
</tr>
<tr>
<td>History of prematurity, very low birth weight, neonatal complications requiring intensive care</td>
</tr>
<tr>
<td>Congenital heart disease (repaired or not)</td>
</tr>
<tr>
<td>Malignancy</td>
</tr>
<tr>
<td>Solid organ or bone marrow transplant</td>
</tr>
<tr>
<td>Systemic diseases possibly associated with arterial hypertension (e.g., neurofibromatosis, tuberous sclerosis, Marfan syndrome, William–Beuren syndrome)</td>
</tr>
<tr>
<td>Management with drugs known to raise blood pressure</td>
</tr>
</tbody>
</table>

rare inherited diseases and that measuring BP at regular intervals is not advised for a quite common condition such as arterial hypertension, which is a substantial cause of heart hypertrophy, arterial stiffening and further organ damage that might be prevented by nonpharmacological and pharmacological intervention [20–23].

Finally, only 35 articles (out of 1000 potentially relevant articles) were included in the final analysis. As noted by two commentaries [13,15*], the Task Force recommendation fails to consider a considerable body of literature that includes relevant observational studies, specifically those addressing intermediate outcomes associated with childhood arterial hypertension, such as carotid artery thickening, left ventricular hypertrophy and urinary protein excretion [20–23].

We believe that the recommendation of the Task Force is inconclusive and flawed because the evidence was too narrowly selected, excluding short-term and relevant observational studies. Hence, we still advise routine screening for high BP at all well child visits, and hope that data from large pediatric cohorts with a long-term follow-up will support our impression.

**Sympathetic nervous system abnormalities in children and adolescents with tendency toward essential hypertension and kidney disease**

The sympathetic arm of the autonomic nervous system, which is mainly implicated in the homeostasis of involuntary processes in response to stressful or emergency situations, plays a critical role in the regulation of BP [24]. Its importance in the short-term regulation of arterial pressure via baroreflex mechanisms is well recognized. However, the role of the sympathetic nervous system in longer-term (days, months and years) BP modulation has been a focus of consideration since the 1970s [24]. Various studies have established that young participants with mild hypertension or normotensive offspring of hypertensive families often exhibit high heart rate and elevated cardiac output. Furthermore, several sympathetic-mediated abnormalities have been reported in these participants, including: a disturbed BP regulation after standing; an altered baroreceptor function; an exaggerated sensitivity of the forearm vasculature to exogenous norepinephrine or of the renal vessels to psychological stimuli; an increased responsiveness of BP to mental stress or dietary potassium restriction; and high circulating catecholamine concentrations during stress [24]. Approximately 30 years ago, a coauthor extensively investigated the BP responses to a stepwise increase in plasma norepinephrine or angiotensin II concentrations induced by exogenous infusions of the vasopressors in young adult patients with mild primary hypertension (and a normal BMI) and in normotensive participants with a negative or positive family history of essential hypertension. Patients and participants with positive history differed from those with negative history of hypertension by a decreased pressor dose of infused norepinephrine and by a different relationship between norepinephrine-induced changes in BP and concomitant plasma norepinephrine levels. In contrast, the pressor dose of infused angiotensin II and the relation between stepwise increasing plasma angiotensin II levels and induced changes in BP was similar in hypertensive patients and in the two groups of normotensive participants (Fig. 1). The aforementioned data indicate the existence of a selectively disturbed noradrenergic BP control in patients with mild primary hypertension and in normotensive offspring of hypertensive families [25,26].

Since then, sophisticated biochemical (norepinephrine spillover), neurophysiological (direct recording of muscle sympathetic nerve traffic) and bioengineering (power spectral analysis of the heart rate signal) approaches have been developed to assess human sympathetic function, allowing new insights in this field [24,27,28]. These data demonstrate a renewed interest of investigators in the field of sympathetic cardiovascular modulation of arterial hypertension and chronic kidney disease. Currently available results indicate the following: sympathetic nervous system overdrive is often modulated by a genetic background; sympathetic overdrive appears very early in the course of primary hypertension; the degree of the sympathetic overactivation is directly related to the severity of
primary hypertension; adrenergic activation displays an adverse impact on end-organ damage and cardiovascular morbidity; in chronic kidney disease, sympathetic activation occurs both in the earlier and in the more advanced clinical stages of the disease and is directly correlated to the severity of the disease; finally, overweight and weight gain are associated with increased sympathetic overdrive.

Catheter-based radiofrequency ablation of renal sympathetic nerves, also known as renal denervation, is a new, apparently promising, strategy that may substantially lower BP in patients with drug-resistant hypertension. Regrettably, the utility of renal denervation has not been proven in drug-resistant arterial hypertension [29**].

Short-term and long-term consequences of arterial hypertension in childhood
Cardiovascular diseases such as stroke or myocardial infarction occur after several years of arterial hypertension. Consequently, these cardiovascular complications first appear in adulthood, indicating that is not possible to directly link BP levels in childhood with cardiovascular disease risk in adulthood. Nevertheless, a correlation between BP and surrogate markers of target-organ damage, such as left ventricular hypertrophy, arterial stiffness or increased urinary protein excretion, is demonstrable in children with arterial hypertension [3].

Severe hypertension in childhood mainly results from secondary causes, such as cardiac or renal disease. Acute symptoms or organ failure are normally not present in children with primary hypertension in this age group primary hypertension is rather mild. Primary hypertension, as in adults, is mainly asymptomatic, or shows few symptoms such as headaches, shortness of breath, epistaxis, and changes in behavior or school performance.

Posterior reversible encephalopathy syndrome is a potentially reversible clinicoradiological entity characterized by insidious onset of headache,
confusion, visual disturbances and seizures associated with brain edema, which predominates in the posterior white matter. Two major factors predispose to this entity in childhood: an acute and severe increase in BP and calcineurin inhibitors. Nephrotic syndrome and acute glomerulonephritides such as postinfectious glomerulonephritis, Immunoglobulin A (IgA) or purpura Schönlein-Henoch nephritis are the most common underlying conditions. As previously stated, altered consciousness (coma, stupor, lethargy and confusion), seizures, headache and visual disturbances are the most distinctive clinical presentation. Symptoms usually develop abruptly and resolve soon with proper management (BP reduction or discontinuation of the causative medication). Cranial MRI is the imaging modality of choice for detecting the entity [30]. The underlying pathophysiologic process appears to be a breakthrough of cerebral blood flow autoregulation, causing vasogenic edema.

The most significant long-term consequence of elevated BP in childhood is the ongoing hypertension into adulthood (tracking of BP [5]), therefore causing cardiovascular, cerebrovascular and renal disease later in life [3,5,6,21,22]. The most evident target-organ damage during childhood and adolescence is left ventricular hypertrophy [8,9]. About 50% of children and adolescents with arterial hypertension have a left ventricular mass index (LVMI) more than the 90th centile and 14% have a LVMI more than the 99th centile [31]. An association between LVMI and systolic ambulatory BP has also been demonstrated in children; this association is stronger than with casual BP measurement [32,33]. Children with white coat hypertension have increased LVMI, representing an intermediate state between hypertensive and normotensive children [34]. Furthermore, prehypertension (BP values between the 90th and 95th centiles) represents an intermediate risk for the development of left ventricular hypertrophy [35].

Hypertensive retinopathy may be found in children with arterial hypertension. Retinal changes with retinal artery narrowing can be observed in children as young as 6–8 years of age.

Preclinical atherosclerosis is assessed by measuring carotid intima–media thickness (cIMT). Several reports document the dependent relationship between cIMT values and childhood BP [22]. Other factors contributing to increased cIMT are BMI and low-density lipoprotein cholesterol [22,23]. Postmortem analysis in the Bogalusa Heart Study revealed that childhood SBP was correlated with fatty streaks and fibrous plaques in young adults [36]. Parameters of arterial distensibility, left ventricular mass, BMI and sedentary lifestyle in childhood were precursors of adult hypertension and target organ damage [37,38,39,40]. Again, these data confirm that cardiovascular risk factors have origins in childhood. Another surrogate marker of impaired vascular function and arterial wall changes (i.e., calcification or atherosclerosis) is arterial stiffness, which is increased in childhood hypertension [41]. Obesity and arterial hypertension have a detrimental effect on arterial stiffness [42].

Childhood hypertension can also impair cognitive function and cerebral vascular reactivity. Lande et al. [43,44] reported an association between arterial hypertension and decreased performance on tests of neurocognitive function, which should be adjusted for potential confounding effects of sleep disordered breathing [45]. Additionally, Adams et al. [46] reported learning and attention problems among children with pediatric primary hypertension. Finally, microalbuminuria is a marker of early renal damage. Childhood hypertension seems to affect microalbuminuria in children [47].

Treatment of arterial hypertension in childhood

Over the last years, management of childhood high BP has been addressed more rigorously than in the past, resulting in clearer consensus recommendations pertaining to appropriate drug management. In children and adolescents with uncomplicated primary hypertension, the goal of therapy should be BP reduction to less than the 95th percentile (despite therapeutic lifestyle modification). In the setting of concurrent diseases, such as diabetes mellitus, or target end-organ damage, BP should be lowered to less than the 90th percentile. On the basis of evidence that more aggressive control may be especially beneficial in slowing renal functional decline in nephropathic participants, the European guidelines advocate for more rigorous BP control, with target values less than the 75th percentile in children with chronic kidney disease and less than the 50th percentile in children with both kidney disease and increased urinary protein excretion [8].

Obviously, participants with asymptomatic primary hypertension may be managed successfully with lifestyle interventions, including extensive counseling regarding the importance of appropriate dietary choices, regular exercise and weight loss. Unfortunately, success may be arduous to achieve with this approach alone and antihypertensive medication is sometimes required.

Considering the high prevalence of secondary hypertension with a rather well-identified mechanism underlying high BP in children and adolescents, a targeted approach to therapy is commonly advocated in an effort to maximize benefit. In patients
with concomitant diseases a specific drug may be particularly beneficial. For example, β-adrenergic blockade is advocated in children with coarctation of the aorta in the period before repair, as these agents reduce the degree of acute postintervention hypertension. In cases with persistent hypertension after correction, β-blockade is usually continued, although treatment with blockers of the renin–angiotensin–aldosterone system may also be well tolerated and effective in these patients. Furthermore, in children with diabetes mellitus or kidney disease, therapy with a blocker of the renin–angiotensin–aldosterone system is advised, especially in cases with pathological urinary protein excretion. In patients affected with a chronic parenchymal kidney disease, the most common indication for antihypertensive drug management in childhood, blocking the renin–angiotensin–aldosterone system is very often insufficient to attain goal BP. In these cases, a diuretic (or a calcium channel-blocker) is added (a β-blocker is added only if the BP goal is still not achieved by combining three drugs) [8]. Table 2 shows the most frequently used antihypertensive drugs in childhood.

Finally, it is also important to consider potential adverse effects prior to initiating therapy. For example, noncardioselective β-adrenergic blockers are generally avoided in participants affected with reactive airway disease due to an increased risk of bronchospasm. On the other hand, there are significant fetal risks associated with the use of blockers of the renin–angiotensin–aldosterone during pregnancy (first trimester exposure might increase the risk of cardiovascular and central nervous system

### Table 2. Antihypertensive drugs that may be administered once a day in the outpatient management of arterial hypertension in pediatric patients with chronic kidney disease

<table>
<thead>
<tr>
<th>Class</th>
<th>Agent</th>
<th>Daily dose (mg)</th>
<th>Body weight (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>10–25</td>
<td>25–40</td>
</tr>
<tr>
<td>Thiazide diuretics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chlortalidone</td>
<td>6–12</td>
<td>12–25</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hydrochlorothiazide</td>
<td>6–12</td>
<td>12–25</td>
</tr>
<tr>
<td>Potassium sparing diuretics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Amiloride</td>
<td>1.3–2.5</td>
<td>2.5–5.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12–25</td>
<td>12–100</td>
</tr>
<tr>
<td></td>
<td>Triamterene</td>
<td>12–25</td>
<td>12–100</td>
</tr>
<tr>
<td>β-adrenergic-blockers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bisoprolol</td>
<td>1.2–2.5</td>
<td>2.5–5.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12–25</td>
<td>25–100</td>
</tr>
<tr>
<td></td>
<td>Metoprolol</td>
<td>10–25</td>
<td>25–100</td>
</tr>
<tr>
<td>Calcium-channel blockers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Amlodipine</td>
<td>2.5–5</td>
<td>5–10</td>
</tr>
<tr>
<td></td>
<td>Lercanidine</td>
<td>5–10</td>
<td>10–20</td>
</tr>
<tr>
<td>Angiotensin II antagonists</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Candesartan</td>
<td>4–8</td>
<td>8–16</td>
</tr>
<tr>
<td></td>
<td></td>
<td>37–75</td>
<td>75–150</td>
</tr>
<tr>
<td></td>
<td>Irbesartan</td>
<td>12–25</td>
<td>[25]–100</td>
</tr>
<tr>
<td></td>
<td>Valsartan</td>
<td>5–40</td>
<td>10–80</td>
</tr>
<tr>
<td>Converting enzyme inhibitors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Benazepril</td>
<td>2.5–5.0</td>
<td>5.0–10</td>
</tr>
<tr>
<td></td>
<td>Fosinopril</td>
<td>1.3–2.5</td>
<td>2.5–10</td>
</tr>
<tr>
<td></td>
<td>Lisinopril</td>
<td>2.5–10</td>
<td>5.0–20</td>
</tr>
<tr>
<td></td>
<td>Quinapril</td>
<td>2.5–5.0</td>
<td>5.0–10</td>
</tr>
<tr>
<td></td>
<td>Ramipril</td>
<td>1.3–2.5</td>
<td>2.5–10</td>
</tr>
</tbody>
</table>

*These drugs are very popular at our institutions.

*Favorable palatability. The prescription of drugs with sustained-release technologies that can reduce dosing frequency to once a day is not advised. The ‘starting dose’ is progressively escalated up to the ‘maximum dose’ every 3–6 weeks.
malformations; second and third trimester exposure interferes with fetal renal function, decreasing fetal urine production and resulting in the fetal renin–angiotensin system blockade syndrome, which is characterized by oligohydramnios, fetal pulmonary hypoplasia and deformational abnormalities [48]. Consequently, discontinuation of these drugs is advised in women who present in early pregnancy, with substitution of an alternate agent if necessary. Furthermore, avoidance of drugs that block the renin–angiotensin–aldosterone system is suggested in women of childbearing age, for whom there are other antihypertensive drugs that would be well tolerated by the fetus.

CONCLUSION

Adult hypertension often begins in childhood. However, overt hypertension is noticeably different in childhood than it is in adults, and requires evaluation and management reflecting differences in the underlying pathophysiology. Although manifest cardiovascular disease related to hypertension is rare during childhood, early onset of this condition undoubtedly contributes to an acceleration of cardiovascular disease and target-organ damage, especially in the presence of the clustering of risk factors associated with overweight. We still recommend that children over 3 years of age should have their BP measured as part of routine healthcare.

Acknowledgements

None.

Financial support and sponsorship

None.

Conflicts of interest

There are no conflicts of interest.

REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

* of special interest
** of outstanding interest

16. A further article debating the controversy about BP screening in children.

This concise editorial addresses the role of ablation of renal sympathetic nerves in patients with arterial hypertension and the possible causes underlying the poor effect of this technique in a recently published blinded, sham-controlled study.


This study highlights the age-related decrease in vascular distensibility from childhood to early adulthood and its related risk factors.


The findings of this study indicate that the adverse influence of excessive adiposity and elevated BP level on left ventricular hypertrophy begins in childhood.


